[1]任 旭,李佳明,丁锦希,等.DRG付费下创新卫生技术除外支付政策的国际经验与启示[J].卫生经济研究,2026,43(01):63-66,71.
　REN Xu,LI Jiaming,DING Jinxi,et al.International Experience and Enlightenment of Exclusion Payment Policy for Innovative Health Technologies under DRG Payment[J].Journal Press of Health Economics Research,2026,43(01):63-66,71.
点击复制

DRG付费下创新卫生技术除外支付政策的国际经验与启示

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
43
期数:
2026年01期
页码:
63-66,71
栏目:
医疗保障
出版日期:
2026-01-06

文章信息/Info

Title:
International Experience and Enlightenment of Exclusion Payment Policy for Innovative Health Technologies under DRG Payment
作者:
任 旭1; 李佳明1; 2; 丁锦希1; 2; 李 伟1; 2
1.中国药科大学国际医药商学院，江苏 南京 211198
2.中国药科大学医药市场准入政策研究中心，江苏 南京 211198
Author(s):
REN Xu;  LI Jiaming;  DING Jinxi;  LI Wei
School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing Jiangsu 211198, China
关键词:
DRG付费; 创新卫生技术; 除外支付政策; 国际经验
Keywords:
DRG payment;  innovative health technologies;  exclusion payment policy;  international experience
分类号:
R19
文献标志码:
A
摘要:
DRG付费在有效控制医保费用的同时，对创新卫生技术的使用产生一定阻碍。对此，我国开始探索创新卫生技术除外支付政策，目前处于起步阶段。可借鉴美国、法国、日本等成熟经验，进一步优化创新卫生技术除外支付政策：围绕“临床获益显著”和“治疗费用高昂”两个核心维度精准遴选创新卫生技术，基于医保基金结余水平差异化设计补偿方案，并建立动态调整机制，保障除外支付政策的可持续发展。
Abstract:
With the comprehensive promotion of DRG payment in China, it not only effectively controls medical insurance cost, but also creates certain barriers to the use of innovative health technologies. In response, China has begun to explore the establishment of the exclusion payment policy, currently in its initial stages. It is necessary to further optimize the exclusion payment policies for innovative health technologies learning from the mature experiences of the United States, France, and Japan, accurately select innovative health technologies based on the two core dimensions of "significant clinical benefit" and "high treatment costs", design compensation schemes based on the balance level of medical insurance funds, and establish a dynamic adjustment mechanism to ensure the sustainability of the excluded payment policy.

参考文献/References:

[1] LindsayA, Bockstedt. The effect of Medicare's New Technology Add-on Payment[M]. The University of Minnesota, 2010.
[2] 胡宏伟，郭宏旺，眭旭东.多元视角下DRG除外支付机制探析[J].中国医疗保险，2022（10）：54-57.
[3] Morey J R, Katana M, Li L, et al. Adoption and trends in the Medicare new technology add-on payment program[J]. Journal of General Internal Medicine, 2021, 36: 2174-2176.
[4] Christopher R, Manz, JustinE, et al. The changing characteristics of technologies covered by Medicare's new technology add-on payment program[J]. JAMA Network Open, 2020, 3(08): e2012569.
[5] Ex, Patricia and Cornelia Henschke. Changing payment instruments and the utilization of new medical technologies[J].The European Journal of Health Economics, 2019, 20: 1029-1039.
[6] 李伟，施慧，丁锦希，等.英国癌症药物基金补偿品种的特征分析及启示[J].中国医院药学杂志，2021，41（14）：1379-1384.
[7] Scheller-Kreinsen D, QuentinW, Busse R. DRG based hospital payment systems and technological innovation in 12 European countries[J]. Value Health, 2011, 14 (08): 1166-1172.
[8] InEk. Fallpauschalen-Katalog 2024[EB/OL].[2025-03-07]. https://www.g-drg.de/ag-drg-system-2024/fallpauschalen-katalog/fallpauschalen-katalog-20242.
[9] Shockwave. CMS proposes additional payment for Shockwave's coronary IVL in hospital inpatient cases[EB/OL].[2025-04-30]. https://shockwavemedical.com/news/cms-proposes-additional-payment-for-shockwaves-coronary-ivl-in-hospital-inpatient-cases/.
[10] Susan Gatehouse. CMS finalizes one-year extension of new technology add-on payments[EB/OL].(2021-10-11)[2025-03-07]. https:// icd10monitor.com/cms-finalizes-one-year-extension-of-new-technology-add-on-payments/.
[11] HAS. Avastin(bevacizumab), anticorps monoclonal-CANCER DU REIN[EB/OL].(2016-06-27)[2025-03-07]. https://www.has-sante.fr/jcms/c_2617560/fr/avastin-bevacizumab-anticorps-monoclonal-cancer-du-rein.
[12] Ministère des finances et des comptes publics Ministère des affaires sociales et de la santé.Validée par le CNP le 26 ao?觠t 2016-Visa CNP 2016-124[EB/OL].(2016-08-30)[2025-03-07]. http://www.omedit-centre.fr/portail/gallery_files/site/136/2953/5062/53 95.pdf.
[13] 于飞，卢静，高辰旭，等.中外创新药物医保支付的比较研究[J].医药导报，2024，43（03）：470-474.
[14] 李水娥，丁锦希，李佳明，等.DRG创新除外机制的关键问题研究[J].中国医疗保险，2023，21（04）：41-48.
[15] 陈薇，方赛男，刘建平，等.国际循证医学证据分级体系的发展与现状[J].中国中西医结合杂志，2017，37（12）：1413-1419.

相似文献/References:

[1]裘凯音,王 佳,王伟红,等.市级统筹背景下DRG付费的公平性研究[J].卫生经济研究,2021,38(12):33.
　QIU Kai-yin,WANG Jia,WANG Wei-hong,et al.Research on the Fairness of DRG Payment at the Municipal Level[J].Journal Press of Health Economics Research,2021,38(01):33.
[2]徐莹波,吴志伟.DRG付费下打造医保基金安全生态圈的思考[J].卫生经济研究,2021,38(12):54.
　XU Ying-bo,WU Zhi-wei.Thoughts on Creating a Security Ecosystem of Medical Insurance Funds under DRG Payment[J].Journal Press of Health Economics Research,2021,38(01):54.
[3]林 敏,夏 燕,朱 婷,等.DRG付费改革对医院运营效率的影响研究[J].卫生经济研究,2021,38(12):62.
　LIN Min,XIA Yan,ZHU Ting,et al.Research on the Influence of DRG Payment Reform on Hospital Operation Efficiency[J].Journal Press of Health Economics Research,2021,38(01):62.
[4]张 弘,丁 科,谢俊明,等.“疗效价值付费”下的中医优势病种DRG付费方案探索[J].卫生经济研究,2021,38(12):75.
　ZHANG Hong,DING Ke,XIE Jun-ming,et al.Exploration of DRG Payment Scheme for Dominant Diseases of Traditional Chinese Medicine under "Efficacy Value Payment"[J].Journal Press of Health Economics Research,2021,38(01):75.
[5]陈非非,张璐莹,俞纯璐,等.DRG付费下创新医疗技术的额外支付机制研究 ——基于国际经验与启示[J].卫生经济研究,2023,40(8):28.
　CHEN Feifei,ZHANG Luying,YU Chunlu,et al.Study on Additional Payment Mechanism for Innovative Medical Technologies under DRG Payment ——Based on International Experience and Enlightenment[J].Journal Press of Health Economics Research,2023,40(01):28.
[6]林振威,吴风琴,程 斌,等.DRG付费下医生异化行为监管的实践及思考[J].卫生经济研究,2024,41(11):36.
　LIN Zhenwei,WU Fengqin,CHENG Bin,et al.Practice and Reflection on the Supervision of Doctor Alienated Behaviors under DRG Payment[J].Journal Press of Health Economics Research,2024,41(01):36.
[7]刘立煌,孟月莉,陈 吟.北京市耗材集采联合DRG付费扩面对住院医疗服务绩效的影响研究[J].卫生经济研究,2026,43(01):14.
　LIU Lihuang,MENG Yueli,CHEN Yin.Impact of the Expansion of Volume-Based Procurement of Consumables Combined with DRG Payment on Inpatient Healthcare Service Performance in Beijing[J].Journal Press of Health Economics Research,2026,43(01):14.
[8]章 倩,郭 文,周 敏,等.DRG付费改革对公立医院医疗服务质量的影响研究[J].卫生经济研究,2026,43(01):44.
　ZHANG Qian,GUO Wen,ZHOU Min,et al.Impact of DRG Payment Reform on the Quality of Medical Services in Public Hospitals[J].Journal Press of Health Economics Research,2026,43(01):44.

更新日期/Last Update: 2026-01-06